

Kate Vandyke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2890056/publications.pdf>

Version: 2024-02-01

43
papers

1,423
citations

304602

22
h-index

330025

37
g-index

43
all docs

43
docs citations

43
times ranked

2544
citing authors

#	ARTICLE	IF	CITATIONS
1	N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer. BMC Cancer, 2018, 18, 939.	1.1	222
2	Dysregulation of bone remodeling by imatinib mesylate. Blood, 2010, 115, 766-774.	0.6	126
3	A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood, 2019, 134, 30-43.	0.6	99
4	The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. Journal of Bone and Mineral Research, 2010, 25, 1759-1770.	3.1	80
5	Identification of Novel EZH2 Targets Regulating Osteogenic Differentiation in Mesenchymal Stem Cells. Stem Cells and Development, 2016, 25, 909-921.	1.1	63
6	Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion. Journal of Molecular Endocrinology, 2012, 48, 229-240.	1.1	55
7	EZH2 deletion in early mesenchyme compromises postnatal bone microarchitecture and structural integrity and accelerates remodeling. FASEB Journal, 2017, 31, 1011-1027.	0.2	55
8	Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo. Neoplasia, 2019, 21, 777-787.	2.3	53
9	Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia, 2009, 23, 994-997.	3.3	52
10	Plasma Adiponectin Levels Are Markedly Elevated in Imatinib-Treated Chronic Myeloid Leukemia (CML) Patients: A Mechanism for Improved Insulin Sensitivity in Type 2 Diabetic CML Patients?. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3763-3767.	1.8	51
11	Imatinib mesylate causes growth plate closure in vivo. Leukemia, 2009, 23, 2155-2159.	3.3	42
12	EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair. Journal of Bone and Mineral Research, 2013, 28, 926-935.	3.1	42
13	HIF-2 α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1. Cancer Research, 2017, 77, 5452-5463.	0.4	41
14	Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. Oncotarget, 2017, 8, 43602-43616.	0.8	37
15	SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma. Neoplasia, 2014, 16, 572-585.	2.3	36
16	Immunomodulatory Properties of Induced Pluripotent Stem Cell-Derived Mesenchymal Cells. Journal of Cellular Biochemistry, 2016, 117, 2844-2853.	1.2	34
17	Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo. Experimental Cell Research, 2015, 332, 24-38.	1.2	31
18	PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. Journal of Hematology and Oncology, 2015, 8, 106.	6.9	29

#	ARTICLE	IF	CITATIONS
19	The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. <i>European Journal of Haematology</i> , 2015, 94, 343-354.	1.1	29
20	The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. <i>Blood Cancer Journal</i> , 2011, 1, e2-e2.	2.8	25
21	Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma. <i>British Journal of Haematology</i> , 2015, 171, 387-399.	1.2	25
22	Prospective Histomorphometric and DXA Evaluation of Bone Remodeling in Imatinib-Treated CML Patients: Evidence for Site-Specific Skeletal Effects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 67-76.	1.8	24
23	The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells. <i>British Journal of Haematology</i> , 2017, 177, 423-440.	1.2	24
24	Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2013, 161, 499-507.	1.2	23
25	Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. <i>Cancer Letters</i> , 2020, 475, 99-108.	3.2	22
26	Engineering Interaction between Bone Marrow Derived Endothelial Cells and Electrospun Surfaces for Artificial Vascular Graft Applications. <i>Biomacromolecules</i> , 2014, 15, 1276-1287.	2.6	18
27	DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment. <i>Neoplasia</i> , 2017, 19, 972-981.	2.3	18
28	Macrophages in multiple myeloma: key roles and therapeutic strategies. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 273-284.	2.7	11
29	Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells & in vivo. <i>Haematologica</i> , 2021, 106, 3176-3187.	1.7	11
30	Desmoglein-2 expression is an independent predictor of poor prognosis patients with multiple myeloma. <i>Molecular Oncology</i> , 2022, 16, 1221-1240.	2.1	9
31	Plant-Derived MINA-05 Inhibits Human Prostate Cancer Proliferation In Vitro and Lymph Node Spread In Vivo. <i>Neoplasia</i> , 2007, 9, 322-331.	2.3	7
32	Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo. <i>Cancers</i> , 2020, 12, 2149.	1.7	6
33	Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma. <i>Cancers</i> , 2020, 12, 3643.	1.7	6
34	LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib. <i>FASEB BioAdvances</i> , 2020, 2, 339-353.	1.3	6
35	Characterization of the role of Samsn1 loss in multiple myeloma development. <i>FASEB BioAdvances</i> , 2020, 2, 554-572.	1.3	3
36	Androgen decreases osteoprotegerin expression in prostate cancer cells. <i>Prostate Cancer and Prostatic Diseases</i> , 2007, 10, 160-166.	2.0	2

#	ARTICLE	IF	CITATIONS
37	The Role of the "Cancer Stem Cell Niche" in Cancer Initiation and Progression. , 2014, , .		2
38	GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice. PLoS ONE, 2020, 15, e0228408.	1.1	2
39	Seed and soil revisited in multiple myeloma. Blood, 2021, 137, 2282-2283.	0.6	1
40	Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. Blood, 2014, 124, 647-647.	0.6	1
41	Macrophages as a potential therapeutic target: Clodronate-liposome treatment inhibits multiple myeloma tumour establishment in vivo. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e96.	0.2	0
42	Dasatinib (Sprycel™) Inhibits Osteoclast Activity in Vitro and in Vivo Via a C-Fms-Dependent and C-Src-Independent Mechanism. Blood, 2008, 112, 3214-3214.	0.6	0
43	Therapeutic Targeting of CCR1 to Prevent Dissemination of Multiple Myeloma Plasma Cells. Blood, 2019, 134, 3099-3099.	0.6	0